Cystic fibrosis: looking for another breakthrough.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000191:economics; D001847:Bone Diseases / Q000209:etiology; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000453:epidemiology / Q000235:genetics / Q000628:therapy; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D003850:Deoxyribonuclease I / Q000191:economics / Q000627:therapeutic use*; D015916:Drainage, Postural; D005544:Forecasting; D015316:Genetic Therapy / Q000191:economics / Q000639:trends; D017048:Health Care Costs; D006801:Humans; D016040:Lung Transplantation / Q000191:economics; D026741:Physical Therapy Modalities; D014031:Tobramycin / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
D000900:Anti-Bacterial Agents; C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D003850:Deoxyribonuclease I; D014031:Tobramycin